Description: T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products based on its proprietary platform. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company offers T2Dx, a bench-top instrument, which has completed a pivotal clinical trial for performing diagnostic tests in sepsis and other applications; and T2Stat, an integrated instrument for hemostasis applications. It is also developing T2Candida panel that has completed a pivotal clinical trial for identifying pathogens associated with sepsis; T2HemoStat panel, which includes a set of hemostasis measurements, including platelet function, clotting time, and clot degradation; and T2Bacteria, a multiplex diagnostic panel that detects the bacterial pathogens associated with sepsis. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Home Page: www.t2biosystems.com
TTOO Technical Analysis
101 Hartwell Avenue
Lexington,
MA
02421
United States
Phone:
781 761 4646
Officers
Name | Title |
---|---|
Mr. John J. Sperzel III, B.Sc. | Pres, CEO & Chairman |
Mr. Michael Terrence Gibbs Esq. | Sr. VP & Gen. Counsel |
Mr. Alec J. Barclay | Sr. VP |
Mr. John M. Sprague CPA | Chief Financial Officer |
Ms. Kelley J. Morgan | Chief People Officer |
Dr. Aparna Jha Ahuja M.D. | Chief Medical Officer & Chairman of Scientific Advisory Board |
Mr. Brett A. Giffin | Chief Commercial Officer |
Dr. Roger Smith Ph.D. | Sr. VP of Science R&D |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 14.5044 |
Price-to-Sales TTM: | 0.3967 |
IPO Date: | 2014-08-07 |
Fiscal Year End: | December |
Full Time Employees: | 182 |